share_log

Guggenheim Downgrades Neumora Therapeutics to Neutral

Benzinga ·  Mar 10 23:01

Guggenheim analyst Yatin Suneja downgrades Neumora Therapeutics (NASDAQ:NMRA) from Buy to Neutral.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment